StreetInsider.com News Articles

Form 4 Disc Medicine, Inc. For: Sep 15 Filed by: Quisel John D

Wed, 16 Sep 2026 18:45:00 -0400

si-local-file:///var/storage/secattach/20260916/27071418.html

Disc Medicine (IRON) PT Raised to $86 at Wells Fargo

Wed, 16 Sep 2026 06:48:20 -0400

Wells Fargo analyst Derek Archila raised the price target on Disc Medicine (NASDAQ: IRON) to $86.00 (from $79.00) while maintaining a Overweight rating.

Form 4 Disc Medicine, Inc. For: Sep 11 Filed by: Bitterman Kevin

Tue, 15 Sep 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260915/27065284.html

Form 144 Disc Medicine, Inc. Filed by: Bitterman Kevin

Fri, 11 Sep 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260911/27052999.html

Form 8-K Disc Medicine, Inc. For: Sep 09

Thu, 10 Sep 2026 08:49:00 -0400

si-local-file:///var/storage/secattach/20260910/27045813.html

H.C. Wainwright Reiterates Buy Rating on Disc Medicine (IRON)

Thu, 10 Sep 2026 06:50:53 -0400

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $120.00 price target on Disc Medicine (NASDAQ: IRON).

The analyst commented: "Initial RESTORE-PV results establish clinical proof-of-concept for DISC-3405 in polycythemia vera (PV) and support continued development of the first anti-TMPRSS6 antibody to demonstrate a reduction in phlebotomy burden. Today, Disc Medicine issued a press release presenting positive initial results from the Phase 2 RESTORE-PV trial of DISC-3405 in polycythemia vera (PV) at the Society of Hematologic Oncology (SOHO) Annual Meeting, establishing clinical proof-of-concept for the first anti-TMPRSS6 antibody to demonstrate a reduction in phlebotomy burden. Among 13 Cohort A patients

BMO Capital Reiterates Outperform Rating on Disc Medicine (IRON)

Thu, 10 Sep 2026 02:59:01 -0400

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $100.00 price target on Disc Medicine (NASDAQ: IRON)

The analyst comments: “Initial DISC-3405 data in polycythemia vera shows potential as a longer-acting treatment that meaningfully reduces patient phlebotomy burden. Dosing of '3405 resulted in an 85% reduction in patient phlebotomies at 26 weeks post treatment (declining from 4.0 in 26 weeks pre-treatment to 0.6). Additionally, 62% of patients (8/13) were phlebotomy-free through 26 weeks. Given '3405's longer dosing profile (Q2W in the cohort A maintenance), we view these reductions as strong and directionally similar to rusfertide, but with potential for

Jefferies Reiterates Buy Rating on Disc Medicine (IRON)

Thu, 10 Sep 2026 02:58:03 -0400

Jefferies analyst Roger Song reiterated a Buy rating and $128.00 price target on Disc Medicine (NASDAQ: IRON)

The analyst comments: “We see the PV initial Ph2 data exceeded our expectations (reach out to us for SOHO PV poster), as we previewed. High phlebotomy-free % and sig reduction were very competitive despite short Tx duration, suggesting faster onset vs. RNA comps and potentially reaching high bars set by newly approved Mimrylo and RNA pipeline, and safety appears to be a clear win on much lower ISR/ anemia vs. comps. With large ~75K treated PV pts among ~150K Dxed in the US and

Disc Medicine reports early RESTORE-PV trial data for PV treatment

Wed, 09 Sep 2026 19:25:16 -0400

Disc Medicine, Inc. (NASDAQ: IRON) presented initial results from its RESTORE-PV Phase 2 trial of DISC-3405 in patients with polycythemia vera (PV) at the Society of Hematologic Oncology (SOHO) annual meeting in Houston, Texas.

The trial enrolled 40 adult participants across two cohorts. Cohort A received DISC-3405 at 300 mg every two weeks, while Cohort B received the same dose every four weeks. Among the 13 Cohort A participants who completed 26 weeks of the study, mean phlebotomy events dropped from 4.0 in the 26 weeks before treatment to 0.6 in the 26 weeks following Day 1 (p<0.0001). Additionally, 61.5% of

Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting

Wed, 09 Sep 2026 19:25:00 -0400

Initial results from RESTORE-PV show DISC-3405 increased hepcidin and lowered serum iron, translating to controlled hematocrit, reduced phlebotomy, and improved symptoms in PV patients
DISC-3405 is the first monoclonal antibody targeting TMPRSS6 that has demonstrated phlebotomy reduction in patients with PV
Disc also presented an encore of the positive results from the Phase 2 RALLY-MF trial of selcodebart (DISC-0974) in patients with anemia of myelofibrosis (MF) and a new systematic literature review characterizing the burden of anemia associated with MF

WATERTOWN, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Disc

Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting

Wed, 09 Sep 2026 19:25:00 -0400

Initial results from RESTORE-PV show DISC-3405 increased hepcidin and lowered serum iron, translating to controlled hematocrit, reduced phlebotomy, and improved symptoms in PV patients
DISC-3405 is the first monoclonal antibody targeting TMPRSS6 that has demonstrated phlebotomy reduction in patients with PV
Disc also presented an encore of the positive results from the Phase 2 RALLY-MF trial of selcodebart (DISC-0974) in patients with anemia of myelofibrosis (MF) and a new systematic literature review characterizing the burden of anemia associated with MF

WATERTOWN, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Disc

Disc Medicine to Participate in Upcoming Investor Conferences

Wed, 02 Sep 2026 08:00:00 -0400

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences:

Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9^th at 8:35 a.m. ET in New York, NY.
Wells Fargo 21^st Annual Healthcare Conference on Thursday, September 10^th at 8:00 a.m. ET in Everett, MA.
Morgan Stanley 24^th Annual Global Healthcare Conference on Monday, September 14^th at 10:45

Disc Medicine to Participate in Upcoming Investor Conferences

Wed, 02 Sep 2026 08:00:00 -0400

Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9^th at 8:35 a.m. ET in New York, NY.
Wells Fargo 21^st Annual Healthcare Conference on Thursday, September 10^th at 8:00 a.m. ET in Everett, MA.
Morgan Stanley 24^th Annual Global Healthcare Conference on Monday, September 14^th at 10:45

Disc Medicine (IRON) Reiterated at Overweight by Cantor Fitzgerald on Selcodebart Potential

Tue, 01 Sep 2026 07:10:27 -0400

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $125.00 price target on Disc Medicine (NASDAQ: IRON).

The analyst commented, "Our physician survey supports broad commercial adoption, with physicians indicating, on average, they'd treat ~44% of patients with MF anemia with selcodebart. Using this estimate across pricing assumptions of $200-300K/yr could lead to peak sales of $1.93B-$2.89B alone, based on our analysis. Even in a more conservative simulation (which also maintains our estimates for the rest of the pipeline), 15% (U.S.) and 14% (EU) peak penetration at 70% PoS could bring our equity valuation up to $148/ share. If bitopertin

Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Mon, 31 Aug 2026 18:00:00 -0400

WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple clinical programs, including an oral presentation of initial data from the RESTORE-PV trial of DISC-3405 in patients with polycythemia vera (PV), at the SOHO Annual Meeting, which will be held in Houston, Texas on September 9-12, 2026.

“We are excited to share the first clinical data from our Phase 2 study of DISC-3405 in polycythemia

Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Mon, 31 Aug 2026 18:00:00 -0400

“We are excited to share the first clinical data from our Phase 2 study of DISC-3405 in polycythemia

Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Mon, 31 Aug 2026 18:00:00 -0400

“We are excited to share the first clinical data from our Phase 2 study of DISC-3405 in polycythemia

Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Mon, 31 Aug 2026 18:00:00 -0400

“We are excited to share the first clinical data from our Phase 2 study of DISC-3405 in polycythemia

Form 4 Disc Medicine, Inc. For: Aug 24 Filed by: Yu Jonathan Yen-Wen

Wed, 26 Aug 2026 20:10:00 -0400

si-local-file:///var/storage/secattach/20260826/26983262.html

Form 4 Disc Medicine, Inc. For: Aug 24 Filed by: Yu Jonathan Yen-Wen

Wed, 26 Aug 2026 20:10:00 -0400

si-local-file:///var/storage/secattach/20260826/26983262.html

Form 4 Disc Medicine, Inc. For: Aug 17 Filed by: Quisel John D

Tue, 18 Aug 2026 18:57:00 -0400

si-local-file:///var/storage/secattach/20260818/26945871.html

Form 4 Disc Medicine, Inc. For: Aug 17 Filed by: Quisel John D

Tue, 18 Aug 2026 18:57:00 -0400

si-local-file:///var/storage/secattach/20260818/26945871.html

Form 144 Disc Medicine, Inc. Filed by: Quisel John D

Mon, 17 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260817/26938398.html

Form 144 Disc Medicine, Inc. Filed by: Quisel John D

Mon, 17 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260817/26938398.html

Disc Medicine (IRON) PT Raised to $90 at Morgan Stanley

Mon, 17 Aug 2026 08:58:13 -0400

Morgan Stanley analyst Sean Laaman raised the price target on Disc Medicine (NASDAQ: IRON) to $90.00 (from $85.00) while maintaining a Overweight rating.